Voya Financial Advisors, Inc. Argenx Se Transaction History

Voya Financial Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $960,562 - $1.2 Million	-3,736 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $184,858 - $262,033	689 Added 22.61%	3,736 $1.02 Million
Q4 2020 Mar 05, 2021	BUY	$248.13 - $308.36 $116,869 - $145,237	471 Added 18.28%	3,047 $907,000
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $9,482 - $11,990	-44 Reduced 1.68%	2,576 $670,000
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $5,225 - $9,541	41 Added 1.59%	2,620 $585,000
Q1 2020 May 15, 2020	BUY	$108.83 - $165.23 $39,287 - $59,648	361 Added 16.28%	2,579 $343,000
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $11,511 - $17,734	108 Added 5.12%	2,218 $359,000
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $11,331 - $15,051	100 Added 4.98%	2,110 $239,000
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $8,855 - $10,901	77 Added 3.98%	2,010 $277,000
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $191,077 - $260,162	1,933 New	1,933 $241,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Voya Financial Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Voya Financial Advisors, Inc. with notifications on news.